kpcczКомплексные проблемы сердечно-сосудистых заболеванийComplex Issues of Cardiovascular Diseases2306-12782587-9537Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”10.17802/2306-1278-2022-11-4-130-138kpccz-1248Research ArticleАНАЛИТИЧЕСКИЙ ОБЗОР. Патологическая физиологияREVIEWS. Pathological physiologyРоль окситоцина в защитной функции сердечно-сосудистой системыRoleofoxytocinin the protective function of the cardiovascular systemhttps://orcid.org/0000-0002-1385-9418БоровлеваО. В.BorovlevaO V.

Боровлева Ольга Владимировна, аспирант кафедры поликлинической терапии и семейной медицины с курсом профессионального образования

ул. Партизана Железняка, 1, Красноярск, 660022

Borovleva Olga V., Postgraduate student at the Departmentof Polyclinic Therapy and Family Medicine

Partizan Zheleznyak St., 1, Krasnoyarsk, 660022

olya8516@gmail.comhttps://orcid.org/0000-0002-0794-2530КаскаеваД. С.KaskayevaD. S.

Каскаева Дарья Сергеевна, кандидат медицинских наук доцент кафедры поликлинической терапии и семейной медицины с курсом профессионального образования

ул. Партизана Железняка, 1, Красноярск, 660022

Kaskayeva Darya S., PhD, Associate Professor at the Department of Polyclinic Therapy and Family Medicine

Partizan Zheleznyak St., 1, Krasnoyarsk, 660022

https://orcid.org/0000-0002-8493-0058ПетроваМ. М.PetrovaM. M.

Петрова Марина Михайловна, доктор медицинских наук профессор кафедры поликлинической терапии и семейной медицины с курсом профессионального образования

ул. Партизана Железняка, 1, Красноярск, 660022

Petrova Marina M., PhD, Professor at the Department of Polyclinic Therapy and Family Medicine

Partizan Zheleznyak St., 1, Krasnoyarsk, 660022

https://orcid.org/0000-0002-7884-2721ЛопатинаО. Л.LopatinaO. L.

Лопатина Ольга Леонидовна, доктор биологических наук доцент Российско-Японской лаборатории изучения социального поведения научно-исследовательского института молекулярной медицины и патобиохимии кафедры биологической химии с курсами медицинской, фармацевтической и токсикологической химии

ул. Партизана Железняка, 1, Красноярск, 660022

Lopatina Olga L., PhD, Associate Professor at the Russian-Japanese Laboratory for Studying Social Behavior, Research Institute for Molecular Medicine and Pathobiochemistry, Department of Biological Chemistry

Partizan Zheleznyak St., 1, Krasnoyarsk, 660022

https://orcid.org/0000-0002-0245-6621БоровлеваА. В.BorovlevaA. V.

Боровлева Анна Владимировна, студент лечебного факультета

ул. Партизана Железняка, 1, Красноярск, 660022

Borovleva Anna V., Student of the Medical Faculty

 

Федеральное государственное бюджетное образовательное учреждение высшего образования «Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University» of the Ministry of Healthcare of the Russian FederationRussian Federation202210012023114130138Copyright © Боровлева О.В., Каскаева Д.С., Петрова М.М., Лопатина О.Л., Боровлева А.В., 20232023Боровлева О.В., Каскаева Д.С., Петрова М.М., Лопатина О.Л., Боровлева А.В.Borovleva O.V., Kaskayeva D.S., Petrova M.M., Lopatina O.L., Borovleva A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nii-kpssz.com/jour/article/view/1248

рецепторами. Доказано воздействие окситоцина на тонус сосудистой стенки, артериальное давление, рост и ремоделирование сосудов, а также участие в сердечно-сосудистой регуляции. Хорошо изучено благоприятное влияние окситоцина на размер инфаркта и сократительную функцию сердца при реперфузии. Механизмы этой кардиопротекции окончательно не определены. Опубликованные данные показывают, что лечение окситоцином улучшает работу сердца, уменьшает апоптоз и воспаление и увеличивает васкуляризацию рубцов. Окситоцин стимулирует дифференцировку стволовых клеток в клоны кардиомиоцитов, а также образование эндотелиальных и гладкомышечных клеток, что в свою очередь способствует ангиогенезу. Благоприятное действие окситоцина может включать увеличение поглощения глюкозы кардиомиоцитами, снижение гипертрофии кардиомиоцитов и окислительного стресса. Окситоцин обладает кардиозащитным действием, которое проявляется в уменьшении воспалительной реакции и улучшении сердечно-сосудистой и метаболической функций. Из-за плейотропной природы эффектов окситоцина последний демонстрирует потенциал в лечении заболеваний сердечно-сосудистой системы. В данном обзоре описаны возможные внутриклеточные механизмы действия окситоцина, участвующие в кардиопротекции.

Oxytocin is synthesized in endothelial cells of the cardiovascular system and exerts its effects by oxytocin receptors. The effect of oxytocin on vascular tone, blood pressure, vascular growth and remodeling, as well as participation in cardiovascular regulation has been proven. The positive effect of oxytocin on infarct size and recovery of contractile function in reperfusion is well studied. It should be noted that the mechanisms of this cardioprotective effect have not yet been studied. Research evidence suggests that oxytocin therapy significantly improves cardiac function, reduces inflammation and apoptosis, and improves scar vascularization. Oxytocin stimulates the transformation of stem cells into clones of cardiomyocytes. Oxytocin promotes angiogenesis by stimulating the formation of endothelial and smooth muscle cells. Increased consumption of glucose by cardiomyocytes, inhibition of cardiomyocyte hypertrophy, and a decrease in oxidative stress are the reasons for the positive effects of oxytocin. Oxytocin reduces inflammation, improves cardiovascular and metabolic function. This is the manifestation of the cardioprotective effect of oxytocin. Potential treatment of cardiovascular diseases with oxytocin is possible due to the pleiotropic nature of oxytocin effects. This review indicates the likely mechanisms of oxytocin action at the cellular level that are involved in cardioprotection.

ОкситоцинКардиопротекцияСердечно-сосудистая системаРецептор окситоцинаСердечно-сосудистая регуляцияЗаболевания сердечно-сосудистой системыИшемическая болезнь сердцаOxytocinCardioprotectionCardiovascular systemOxytocin receptorCardiovascular regulationCardiovascular diseasesCoronary artery diseaseReferencesGutkowska J., Jankowski M., Antunes-Rodrigues J. The role of oxytocin in cardiovascular regulation. Braz J Med Biol Res. 2014; 47(3): 206-214.Gutkowska J., Jankowski M., Antunes-Rodrigues J. The role of oxytocin in cardiovascular regulation. Braz J Med Biol Res. 2014; 47(3): 206-214.Houshmand F., Faghihi M., Zahediasl S. Role of atrial natriuretic Peptide in oxytocin induced cardioprotection. Heart Lung Circ. 2015; 24(1): 86-93. doi: 10.1016/j.hlc.2014.05.023.Houshmand F., Faghihi M., Zahediasl S. Role of atrial natriuretic Peptide in oxytocin induced cardioprotection. Heart Lung Circ. 2015; 24(1): 86-93. doi: 10.1016/j.hlc.2014.05.023.Klenerova V., Chottova-Dvorakova M., Skopek P., Sida P., Mistrova E., Slavikova J., et al. Expression of heart oxytocin receptor and its mRNA in two rat strains with different activity of HPA axis. Neuro Endocrinol Lett. 2011; 32(6): 805-810.Klenerova V., Chottova-Dvorakova M., Skopek P., Sida P., Mistrova E., Slavikova J., et al. Expression of heart oxytocin receptor and its mRNA in two rat strains with different activity of HPA axis. Neuro Endocrinol Lett. 2011; 32(6): 805-810.Jankowski M., Wang D., Danalache B., Gangal M., Gutkowska J. Cardiac oxytocin receptor blockade stimulates adverse cardiac remodeling in ovariectomized spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010; 299(2): 265-274. doi: 10.1152/ajpheart.00487.2009.Jankowski M., Wang D., Danalache B., Gangal M., Gutkowska J. Cardiac oxytocin receptor blockade stimulates adverse cardiac remodeling in ovariectomized spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010; 299(2): 265-274. doi: 10.1152/ajpheart.00487.2009.Lipari A., Farina E., Gerbino A., Lipari L. Atrial natriuretic peptide (ANP) and oxytocin-expression in the adult rat and mouse cerebellum. Cerebellum Ataxias. 2015; 2: 12. doi: 10.1186/s40673-015-0031-1.Lipari A., Farina E., Gerbino A., Lipari L. Atrial natriuretic peptide (ANP) and oxytocin-expression in the adult rat and mouse cerebellum. Cerebellum Ataxias. 2015; 2: 12. doi: 10.1186/s40673-015-0031-1.Wang P., Wang S.C., Yang H., Lv C., Jia S., Liu X., Wang X., Meng D., Qin D., Zhu H., Wang Y.F. Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways. Front Neurosci. 2019; 13: 454. doi: 10.3389/fnins.2019.00454.Wang P., Wang S.C., Yang H., Lv C., Jia S., Liu X., Wang X., Meng D., Qin D., Zhu H., Wang Y.F. Therapeutic Potential of Oxytocin in Atherosclerotic Cardiovascular Disease: Mechanisms and Signaling Pathways. Front Neurosci. 2019; 13: 454. doi: 10.3389/fnins.2019.00454.Cattaneo M.G., Lucci G., Vicentini L.M. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res. 2009; 315(18): 3210-9. doi: 10.1016/j.yexcr.2009.06.022.Cattaneo M.G., Lucci G., Vicentini L.M. Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. Exp Cell Res. 2009; 315(18): 3210-9. doi: 10.1016/j.yexcr.2009.06.022.Japundžić-Žigon N., Lozić M., Šarenac O., Murphy D. Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review. Curr Neuropharmacol. 2020; 18(1): 14-33. doi: 10.2174/1570159X17666190717150501.Japundžić-Žigon N., Lozić M., Šarenac O., Murphy D. Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review. Curr Neuropharmacol. 2020; 18(1): 14-33. doi: 10.2174/1570159X17666190717150501.Szczepanska-Sadowska E., Wsol A., Cudnoch-Jedrzejewska A., Żera T. Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation. Int J Mol Sci. 2021; 22 (21): 11465. doi: 10.3390/ijms222111465.Szczepanska-Sadowska E., Wsol A., Cudnoch-Jedrzejewska A., Żera T. Complementary Role of Oxytocin and Vasopressin in Cardiovascular Regulation. Int J Mol Sci. 2021; 22 (21): 11465. doi: 10.3390/ijms222111465.Jankowski M., Danalache B.A., Plante E., Menaouar A., Florian M., Tan J.J., Grygorczyk R., Broderick T.L., Gutkowska J. Dissociation of natriuresis and diuresis by oxytocin molecular forms in rats. PLoS One. 2019; 14(7): e0219205. doi: 10.1371/journal.pone.0219205.Jankowski M., Danalache B.A., Plante E., Menaouar A., Florian M., Tan J.J., Grygorczyk R., Broderick T.L., Gutkowska J. Dissociation of natriuresis and diuresis by oxytocin molecular forms in rats. PLoS One. 2019; 14(7): e0219205. doi: 10.1371/journal.pone.0219205.Takayanagi Y., Kasahara Y., Onaka T., Takahashi N., Kawada T., Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport. 2008; 19(9): 951955. doi: 10.1097/WNR.0b013e3283021ca9.Takayanagi Y., Kasahara Y., Onaka T., Takahashi N., Kawada T., Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport. 2008; 19(9): 951955. doi: 10.1097/WNR.0b013e3283021ca9.Rubattu S., Calvieri C., Pagliaro B., Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013; 31(6): 1061-1072. doi: 10.1097/HJH.0b013e32835ed5eb.Rubattu S., Calvieri C., Pagliaro B., Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013; 31(6): 1061-1072. doi: 10.1097/HJH.0b013e32835ed5eb.Buemann B., Uvnäs-Moberg K. Oxytocin may have a therapeutical potential against cardiovascular disease. Possible pharmaceutical and behavioral approaches. Med Hypotheses. 2020; 138: 1095-1097. doi: 10.1016/j.mehy.2020.109597.Buemann B., Uvnäs-Moberg K. Oxytocin may have a therapeutical potential against cardiovascular disease. Possible pharmaceutical and behavioral approaches. Med Hypotheses. 2020; 138: 1095-1097. doi: 10.1016/j.mehy.2020.109597.Szczepanska-Sadowska E., Cudnoch-Jedrzejewska A., Wsol A. The role of oxytocin and vasopressin in the pathophysiology of heart failure in pregnancy and in fetal and neonatal life. Am J Physiol Heart Circ Physiol. 2020; 318(3): 639-651. doi: 10.1152/ajpheart.00484.2019.Szczepanska-Sadowska E., Cudnoch-Jedrzejewska A., Wsol A. The role of oxytocin and vasopressin in the pathophysiology of heart failure in pregnancy and in fetal and neonatal life. Am J Physiol Heart Circ Physiol. 2020; 318(3): 639-651. doi: 10.1152/ajpheart.00484.2019.Gutkowska J., Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol. 2012; 24(4): 599-608. doi: 10.1111/j.1365-2826.2011.02235.x.Gutkowska J., Jankowski M. Oxytocin revisited: its role in cardiovascular regulation. J Neuroendocrinol. 2012; 24(4): 599-608. doi: 10.1111/j.1365-2826.2011.02235.x.Pyner S. The heart is lost without the hypothalamus. Handb Clin Neurol. 2021;182:355-67. doi: 10.1016/B978-012-819973-2.00024-1. PubMed PMID: 34266605.Pyner S. The heart is lost without the hypothalamus. Handb Clin Neurol. 2021;182:355-67. doi: 10.1016/B978-012-819973-2.00024-1. PubMed PMID: 34266605.Danalache B.A., Yu C., Gutkowska J., Jankowski M. Oxytocin-Gly-Lys-Arg stimulates cardiomyogenesis by targeting cardiac side population cells. J Endocrinol. 2014; 220(3): 277-89. doi: 10.1530/JOE-13-0305.Danalache B.A., Yu C., Gutkowska J., Jankowski M. Oxytocin-Gly-Lys-Arg stimulates cardiomyogenesis by targeting cardiac side population cells. J Endocrinol. 2014; 220(3): 277-89. doi: 10.1530/JOE-13-0305.Bollini S., Smart N., Riley P.R. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol. 2011; 50(2): 296-303. doi: 10.1016/j.yjmcc.2010.07.006.Bollini S., Smart N., Riley P.R. Resident cardiac progenitor cells: at the heart of regeneration. J Mol Cell Cardiol. 2011; 50(2): 296-303. doi: 10.1016/j.yjmcc.2010.07.006.Noiseux N., Borie M., Desnoyers A., Menaouar A., Stevens L.M., Mansour S., Danalache B.A., Roy D.C., Jankowski M., Gutkowska J. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology. 2012; 153(11): 5361-5372. doi: 10.1210/en.2012-1402.Noiseux N., Borie M., Desnoyers A., Menaouar A., Stevens L.M., Mansour S., Danalache B.A., Roy D.C., Jankowski M., Gutkowska J. Preconditioning of stem cells by oxytocin to improve their therapeutic potential. Endocrinology. 2012; 153(11): 5361-5372. doi: 10.1210/en.2012-1402.Zhu H., Zhang Z., Liu Y., Chen Y., Tan Y. Molecular mechanism of cardiac differentiation in P19 embryonal carcinoma cells regulated by Foxa2. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013; 38(4): 356-364. doi: 10.3969/j.issn.1672-7347.2013.04.004.Zhu H., Zhang Z., Liu Y., Chen Y., Tan Y. Molecular mechanism of cardiac differentiation in P19 embryonal carcinoma cells regulated by Foxa2. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013; 38(4): 356-364. doi: 10.3969/j.issn.1672-7347.2013.04.004.Jankowski M., Broderick T.L., Gutkowska J. The Role of Oxytocin in Cardiovascular Protection. Front Psychol. 2020; 11: 21-39. doi: 10.3389/fpsyg.2020.02139.Jankowski M., Broderick T.L., Gutkowska J. The Role of Oxytocin in Cardiovascular Protection. Front Psychol. 2020; 11: 21-39. doi: 10.3389/fpsyg.2020.02139.Ye J., Boyle A., Shih H., Sievers R.E., Zhang Y., Prasad M., Su H., Zhou Y., Grossman W., Bernstein H.S., Yeghiazarians Y. Sca-1+ cardiosphere-derived cells are enriched for Isl1expressing cardiac precursors and improve cardiac function after myocardial injury. PLoS One. 2012; 7(1): e30329. doi: 10.1371/journal.pone.0030329.Ye J., Boyle A., Shih H., Sievers R.E., Zhang Y., Prasad M., Su H., Zhou Y., Grossman W., Bernstein H.S., Yeghiazarians Y. Sca-1+ cardiosphere-derived cells are enriched for Isl1expressing cardiac precursors and improve cardiac function after myocardial injury. PLoS One. 2012; 7(1): e30329. doi: 10.1371/journal.pone.0030329.Danalache B.A., Gutkowska J., Slusarz M.J., Berezowska I., Jankowski M. Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide. PLoS One. 2010; 5(10): e13643. doi: 10.1371/journal.pone.0013643.Danalache B.A., Gutkowska J., Slusarz M.J., Berezowska I., Jankowski M. Oxytocin-Gly-Lys-Arg: a novel cardiomyogenic peptide. PLoS One. 2010; 5(10): e13643. doi: 10.1371/journal.pone.0013643.Branco A.F., Pereira S.P., Gonzalez S., Gusev O., Rizvanov A.A., Oliveira P.J. Gene Expression Profiling of H9c2 Myoblast Differentiation towards a Cardiac-Like Phenotype. PLoS One. 2015; 10(6): e0129303. doi: 10.1371/journal.pone.0129303.Branco A.F., Pereira S.P., Gonzalez S., Gusev O., Rizvanov A.A., Oliveira P.J. Gene Expression Profiling of H9c2 Myoblast Differentiation towards a Cardiac-Like Phenotype. PLoS One. 2015; 10(6): e0129303. doi: 10.1371/journal.pone.0129303.Bøtker H.E., Hausenloy D., Andreadou I., Antonucci S., Boengler K., Davidson S.M., Deshwal S., Devaux Y., Di Lisa F., Di Sante M., Efentakis P., Femminò S., GarcíaDorado D., Giricz Z., Ibanez B., Iliodromitis E., Kaludercic N., Kleinbongard P., Neuhäuser M., Ovize M., Pagliaro P., Rahbek-Schmidt M., Ruiz-Meana M., Schlüter K.D., Schulz R., Skyschally A., Wilder C., Yellon D.M., Ferdinandy P., Heusch G. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018; 113(5): 39. doi: 10.1007/s00395-018-0696-8.Bøtker H.E., Hausenloy D., Andreadou I., Antonucci S., Boengler K., Davidson S.M., Deshwal S., Devaux Y., Di Lisa F., Di Sante M., Efentakis P., Femminò S., GarcíaDorado D., Giricz Z., Ibanez B., Iliodromitis E., Kaludercic N., Kleinbongard P., Neuhäuser M., Ovize M., Pagliaro P., Rahbek-Schmidt M., Ruiz-Meana M., Schlüter K.D., Schulz R., Skyschally A., Wilder C., Yellon D.M., Ferdinandy P., Heusch G. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018; 113(5): 39. doi: 10.1007/s00395-018-0696-8.Gonzalez-Reyes A., Menaouar A., Yip D., Danalache B., Plante E., Noiseux N., Gutkowska J., Jankowski M. Molecular mechanisms underlying oxytocin-induced cardiomyocyte protection from simulated ischemia-reperfusion. Mol Cell Endocrinol. 2015; 412: 170-181. doi: 10.1016/j.mce.2015.04.028.Gonzalez-Reyes A., Menaouar A., Yip D., Danalache B., Plante E., Noiseux N., Gutkowska J., Jankowski M. Molecular mechanisms underlying oxytocin-induced cardiomyocyte protection from simulated ischemia-reperfusion. Mol Cell Endocrinol. 2015; 412: 170-181. doi: 10.1016/j.mce.2015.04.028.Gravina F.S., Jobling P., Kerr K.P., de Oliveira R.B., Parkington H.C., van Helden D.F. Oxytocin depolarizes mitochondria in isolated myometrial cells. Exp Physiol. 2011; 96(9): 949-956. doi: 10.1113/expphysiol.2011.058388.Gravina F.S., Jobling P., Kerr K.P., de Oliveira R.B., Parkington H.C., van Helden D.F. Oxytocin depolarizes mitochondria in isolated myometrial cells. Exp Physiol. 2011; 96(9): 949-956. doi: 10.1113/expphysiol.2011.058388.Quan H.X., Jin J.Y., Wen J.F., Cho K.W. Beta1adrenergic receptor activation decreases ANP release via cAMP-Ca2+ signaling in perfused beating rabbit atria. Life Sci. 2010; 87(7-8): 246-253. doi: 10.1016/j.lfs.2010.06.022.Quan H.X., Jin J.Y., Wen J.F., Cho K.W. Beta1adrenergic receptor activation decreases ANP release via cAMP-Ca2+ signaling in perfused beating rabbit atria. Life Sci. 2010; 87(7-8): 246-253. doi: 10.1016/j.lfs.2010.06.022.Kobayashi H., Yasuda S., Bao N., Iwasa M., Kawamura I., Yamada Y., Yamaki T., Sumi S., Ushikoshi H., Nishigaki K., Takemura G., Fujiwara T., Fujiwara H., Minatoguchi S. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovasc Pharmacol. 2009; 54(6): 510-519. doi: 10.1097/FJC.0b013e3181bfac02.Kobayashi H., Yasuda S., Bao N., Iwasa M., Kawamura I., Yamada Y., Yamaki T., Sumi S., Ushikoshi H., Nishigaki K., Takemura G., Fujiwara T., Fujiwara H., Minatoguchi S. Postinfarct treatment with oxytocin improves cardiac function and remodeling via activating cell-survival signals and angiogenesis. J Cardiovasc Pharmacol. 2009; 54(6): 510-519. doi: 10.1097/FJC.0b013e3181bfac02.Moraes M.S., Costa P.E., Batista W.L., Paschoalin T., Curcio M.F., Borges R.E., Taha M.O., Fonseca F.V., Stern A., Monteiro H.P. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Arch Biochem Biophys. 2014; 558: 14-27. doi: 10.1016/j.abb.2014.06.011.Moraes M.S., Costa P.E., Batista W.L., Paschoalin T., Curcio M.F., Borges R.E., Taha M.O., Fonseca F.V., Stern A., Monteiro H.P. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis. Arch Biochem Biophys. 2014; 558: 14-27. doi: 10.1016/j.abb.2014.06.011.Gélinas R., Mailleux F., Dontaine J., Bultot L., Demeulder B., Ginion A., Daskalopoulos E.P., Esfahani H., Dubois-Deruy E., Lauzier B., Gauthier C., Olson A.K., Bouchard B., Des Rosiers C., Viollet B., Sakamoto K., Balligand J.-L., Vanoverschelde J.-L., Beauloye C., Horman S., Bertrand L. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun. 2018; 9(1): 374. doi: 10.1038/s41467-017-02795-4.Gélinas R., Mailleux F., Dontaine J., Bultot L., Demeulder B., Ginion A., Daskalopoulos E.P., Esfahani H., Dubois-Deruy E., Lauzier B., Gauthier C., Olson A.K., Bouchard B., Des Rosiers C., Viollet B., Sakamoto K., Balligand J.-L., Vanoverschelde J.-L., Beauloye C., Horman S., Bertrand L. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun. 2018; 9(1): 374. doi: 10.1038/s41467-017-02795-4.Negro A., Dodge-Kafka K., Kapiloff M.S. Signalosomes as Therapeutic Targets. Prog Pediatr Cardiol. 2008; 25(1): 5156. doi: 10.1016/j.ppedcard.2007.11.012.Negro A., Dodge-Kafka K., Kapiloff M.S. Signalosomes as Therapeutic Targets. Prog Pediatr Cardiol. 2008; 25(1): 5156. doi: 10.1016/j.ppedcard.2007.11.012.Pagliaro P., Femminò S., Popara J., Penna C. Mitochondria in Cardiac Postconditioning. Front Physiol. 2018; 9: 287. doi: 10.3389/fphys.2018.00287.Pagliaro P., Femminò S., Popara J., Penna C. Mitochondria in Cardiac Postconditioning. Front Physiol. 2018; 9: 287. doi: 10.3389/fphys.2018.00287.Quinlan C.L., Costa A.D., Costa C.L., Pierre S.V., Dos Santos P., Garlid K.D. Conditioning the heart induces formation of signalosomes that interact with mitochondria to open mitoKATP channels. Am J Physiol Heart Circ Physiol. 2008; 295(3): 953-961. doi: 10.1152/ajpheart.00520.2008.Quinlan C.L., Costa A.D., Costa C.L., Pierre S.V., Dos Santos P., Garlid K.D. Conditioning the heart induces formation of signalosomes that interact with mitochondria to open mitoKATP channels. Am J Physiol Heart Circ Physiol. 2008; 295(3): 953-961. doi: 10.1152/ajpheart.00520.2008.Rimoldi V., Reversi A., Taverna E., Rosa P., Francolini M., Cassoni P., Parenti M., Chini B. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene. 2003; 22(38): 6054-6060. doi: 10.1038/sj.onc.1206612.Rimoldi V., Reversi A., Taverna E., Rosa P., Francolini M., Cassoni P., Parenti M., Chini B. Oxytocin receptor elicits different EGFR/MAPK activation patterns depending on its localization in caveolin-1 enriched domains. Oncogene. 2003; 22(38): 6054-6060. doi: 10.1038/sj.onc.1206612.Sanon V.P., Sawaki D., Mjaatvedt C.H., Jourdan-Le Saux C. Myocardial tissue caveolae. Compr Physiol. 2015; 5(2): 871-886. doi: 10.1002/cphy.c140050.Sanon V.P., Sawaki D., Mjaatvedt C.H., Jourdan-Le Saux C. Myocardial tissue caveolae. Compr Physiol. 2015; 5(2): 871-886. doi: 10.1002/cphy.c140050.Svanström M.C., Biber B., Hanes M., Johansson G., Näslund U., Bålfors E.M. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008; 100(5): 683-689. doi: 10.1093/bja/aen071.Svanström M.C., Biber B., Hanes M., Johansson G., Näslund U., Bålfors E.M. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth. 2008; 100(5): 683-689. doi: 10.1093/bja/aen071.Gutkowska J., Granger J.P., Lamarca B.B., Danalache B.A., Wang D., Jankowski M. Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade. J Hypertens. 2011; 29(6): 1203-1212. doi: 10.1097/HJH.0b013e3283468392.Gutkowska J., Granger J.P., Lamarca B.B., Danalache B.A., Wang D., Jankowski M. Changes in cardiac structure in hypertension produced by placental ischemia in pregnant rats: effect of tumor necrosis factor blockade. J Hypertens. 2011; 29(6): 1203-1212. doi: 10.1097/HJH.0b013e3283468392.Song Z., Albers H.E. Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery. Front Neuroendocrinol. 2018; 51: 14-24. doi: 10.1016/j.yfrne.2017.10.004.Song Z., Albers H.E. Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery. Front Neuroendocrinol. 2018; 51: 14-24. doi: 10.1016/j.yfrne.2017.10.004.Natochin Y.V., Shakhmatova E.I., Bogolepova A.E. Mechanism of Natriuretic Effect of Oxytocin. Bull Exp Biol Med. 2020; 168(5): 634-636. doi: 10.1007/s10517-020-04768-y.Natochin Y.V., Shakhmatova E.I., Bogolepova A.E. Mechanism of Natriuretic Effect of Oxytocin. Bull Exp Biol Med. 2020; 168(5): 634-636. doi: 10.1007/s10517-020-04768-y.Natochin Y.V., Golosova D.V. Vasopressin receptor subtypes and renal sodium transport. Vitam Horm. 2020; 113: 239-258. doi: 10.1016/bs.vh.2019.08.013.Natochin Y.V., Golosova D.V. Vasopressin receptor subtypes and renal sodium transport. Vitam Horm. 2020; 113: 239-258. doi: 10.1016/bs.vh.2019.08.013.Iovino M., Messana T., Tortora A., Giusti C., Lisco G., Giagulli V.A., Guastamacchia E., De Pergola G., Triggiani V. Oxytocin Signaling Pathway: From Cell Biology to Clinical Implications. Endocr Metab Immune Disord Drug Targets. 2021; 21(1): 91-110. doi: 10.2174/1871530320666200520093730.Iovino M., Messana T., Tortora A., Giusti C., Lisco G., Giagulli V.A., Guastamacchia E., De Pergola G., Triggiani V. Oxytocin Signaling Pathway: From Cell Biology to Clinical Implications. Endocr Metab Immune Disord Drug Targets. 2021; 21(1): 91-110. doi: 10.2174/1871530320666200520093730.Ondrejcakova M., Ravingerova T., Bakos J., Pancza D., Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol. 2009; 87(2): 137-142. doi: 10.1139/Y08-108.Ondrejcakova M., Ravingerova T., Bakos J., Pancza D., Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol. 2009; 87(2): 137-142. doi: 10.1139/Y08-108.Jovanovic P., Spasojevic N., Puskas N., Stefanovic B., Dronjak S. Oxytocin modulates the expression of norepinephrine transporter, β. Peptides. 2019; 111:132-141. doi: 10.1016/j. peptides.2018.06.008.Jovanovic P., Spasojevic N., Puskas N., Stefanovic B., Dronjak S. Oxytocin modulates the expression of norepinephrine transporter, β. Peptides. 2019; 111:132-141. doi: 10.1016/j. peptides.2018.06.008.Penna C., Granata R., Tocchetti C.G., Gallo M.P., Alloatti G., Pagliaro P. Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. Curr Drug Targets. 2015; 16(8): 843-867. doi: 10.2174/1389450116666150309115536.Penna C., Granata R., Tocchetti C.G., Gallo M.P., Alloatti G., Pagliaro P. Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. Curr Drug Targets. 2015; 16(8): 843-867. doi: 10.2174/1389450116666150309115536.Ruiz-Meana M., Boengler K., Garcia-Dorado D.., Hausenloy D.J., Kaambre T., Kararigas G., Perrino C., Schulz R., Ytrehus K. Ageing, sex, and cardioprotection. Br J Pharmacol. 2020; 177(23): 5270-5286. doi: 10.1111/bph.14951.Ruiz-Meana M., Boengler K., Garcia-Dorado D.., Hausenloy D.J., Kaambre T., Kararigas G., Perrino C., Schulz R., Ytrehus K. Ageing, sex, and cardioprotection. Br J Pharmacol. 2020; 177(23): 5270-5286. doi: 10.1111/bph.14951.Kleinbongard P., Bøtker H.E., Ovize M., Hausenloy D.J., Heusch G. Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? Br J Pharmacol. 2020; 177(23): 5252-5269. doi: 10.1111/bph.14839.Kleinbongard P., Bøtker H.E., Ovize M., Hausenloy D.J., Heusch G. Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? Br J Pharmacol. 2020; 177(23): 5252-5269. doi: 10.1111/bph.14839.Femminò S., Pagliaro P., Penna C. Obesity and Cardioprotection. Curr Med Chem. 2020; 27(2): 230-239. doi: 10.2174/0929867326666190325094453.Femminò S., Pagliaro P., Penna C. Obesity and Cardioprotection. Curr Med Chem. 2020; 27(2): 230-239. doi: 10.2174/0929867326666190325094453.Penna C., Andreadou I., Aragno M., Beauloye C., Bertrand L., Lazou A., Falcão-Pires I., Bell R., Zuurbier C.J., Pagliaro P., Hausenloy D.J. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br JPenna C., Andreadou I., Aragno M., Beauloye C., Bertrand L., Lazou A., Falcão-Pires I., Bell R., Zuurbier C.J., Pagliaro P., Hausenloy D.J. Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br JPharmacol. 2020; 177(23): 5312-5335. doi: 10.1111/bph.14993.Pharmacol. 2020; 177(23): 5312-5335. doi: 10.1111/bph.14993.Davidson S.M., Ferdinandy P., Andreadou I., Bøtker H.E., Heusch G., Ibáñez B., Ovize M., Schulz R., Yellon D.M., Hausenloy D.J., Garcia-Dorado D.; CARDIOPROTECTION COST Action (CA16225). Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 73(1): 89-99. doi: 10.1016/j.jacc.2018.09.086.Davidson S.M., Ferdinandy P., Andreadou I., Bøtker H.E., Heusch G., Ibáñez B., Ovize M., Schulz R., Yellon D.M., Hausenloy D.J., Garcia-Dorado D.; CARDIOPROTECTION COST Action (CA16225). Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 73(1): 89-99. doi: 10.1016/j.jacc.2018.09.086.

The authors declare that there are no conflicts of interest present.